What does BioCryst do?
BioCryst is a commercial-stage biotech company that is committed to delivering extraordinary medicines that help patients live ordinary lives. At BioCryst, we are passionate about advancing novel therapeutics for patients with rare and serious diseases.
What does BioCryst make?
RABIVAP
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases….BioCryst Pharmaceuticals.
| Type | Public |
|---|---|
| Products | RABIVAP |
| Revenue | $49 Million(2019) |
| Number of employees | 110 |
| Website | www.biocryst.com |
Who is CEO of Bcrx?
CEO Jon Stonehouse
(BCRX) CEO Jon Stonehouse on Q3 2021 Results – Earnings Call Transcript.
Who owns BioCryst Pharmaceuticals?
Top 10 Owners of BioCryst Pharmaceuticals Inc
| Stockholder | Stake | Shares bought / sold |
|---|---|---|
| The Vanguard Group, Inc. | 5.06% | +62,267 |
| SSgA Funds Management, Inc. | 3.97% | +852,551 |
| Sarissa Capital Management LP | 2.19% | -334,300 |
| HealthCor Management LP | 2.15% | +601,370 |
Is BCRX a good investment?
The financial health and growth prospects of BCRX, demonstrate its potential to underperform the market. It currently has a Growth Score of C. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of D.
Is BCRX a buy?
BioCryst Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.
How many employees does BioCryst have?
80 employees
BioCryst has over 80 employees spread across their two locations in Birmingham, Alabama and Durham, North Carolina.
How many shares does BioCryst have?
BioCryst Pharmaceuticals, Inc. (US:BCRX) has 405 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 117,641,361 shares.
Will BioCryst go up?
Will Biocryst Pharmaceuticals stock price grow / rise / go up? Yes. The BCRX stock price can go up from 13.010 USD to 13.049 USD in one year.
Why is BioCryst stock falling?
Shares of BioCryst (NASDAQ:BCRX), a biopharmaceutical company, are falling after the company reported third-quarter earnings results. A drop in top-line revenue and softer-than-expected guidance aren’t sitting well with investors, who have driven the stock 16.5% lower as of 11:50 a.m. on Wednesday.
Is BioCryst a good company?
Zacks’ proprietary data indicates that BioCryst Pharmaceuticals, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the BCRX shares relative to the market in the next few months. The financial health and growth prospects of BCRX, demonstrate its potential to underperform the market.
Is Bcrx a buy?